Lucid Diagnostics, a subsidiary of PAVmed Inc., was founded with the mission to pioneer cancer-prevention diagnostics. The company focuses on developing non-invasive, office-based diagnostic tests for esophageal cancer biomarkers. Their flagship products, EsoCheck and EsoGuard, are designed to sample and diagnose esophageal cells, particularly targeting Barrett's Esophagus. Lucid Diagnostics aims to improve and save lives by addressing unmet clinical needs through innovative medical technologies.
Notable affiliated individuals include executives from PAVmed Inc., who provide strategic oversight. The company has achieved significant milestones, including the development and commercialization of its breakthrough devices. Lucid Diagnostics has made a substantial impact in the medical diagnostics field by offering cost-efficient, timely solutions that advance from concept to market. Their innovative approach has the potential to transform early cancer detection and prevention.
